slides · global inventory
Traction
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,471
Current window 6,001-6,030
Pages 350
Rows per page 30
Slide type
6,001-6,030 of 10,471
22
The slide uses competitive benchmarking to establish authority in the restructuring market.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Competition1 hit
24
The slide uses a split-layout to combine qualitative value propositions with a quantitative ranking table.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
26
The slide highlights financial resilience and scalability through market cycles.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
11
The chart illustrates the mechanism of action and efficacy of NXC-201 (formerly HBI0101) in treating AL Amyloidosis.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
27
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
28
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
35
Includes a process diagram illustrating the mechanism of action of IMX-110 in turning cold tumors hot.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
36
Includes Kaplan-Meier survival curves and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
38
Includes waterfall charts and longitudinal patient response plots. Source note provided at bottom.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
40
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a small sample size (n=4).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
46
Includes two sets of charts: tumor volume over time and survival curves. References specific dosing schedules and study parameters.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
55
The slide uses a combination of expert testimonials and a comparative clinical trial table to validate the outpatient administration model.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
11
The slide uses a consistent color palette to distinguish business segments and financial metrics across three distinct bar charts.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · FinancialsLoop · Pattern Hunter1 hit
12
The slide uses a series of bar charts to display performance trends over five quarters (3Q22 to 3Q23).Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · FinancialsLoop · Pattern Hunter1 hit
16
The slide uses a combination of bar charts and line overlays to show performance metrics from 2016 to 3Q23/LTM.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · FinancialsLoop · Pattern Hunter1 hit
18
The slide uses a dual-column layout: a table for AUM breakdown and a horizontal timeline for historical growth milestones.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · Solution1 hit
23
LTM refers to the last twelve months as of September 30, 2023.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · Solution1 hit
29
The slide uses a combination of grouped bar charts and a line overlay to demonstrate segment performance and overall margin stability.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · The Ask1 hit
11
Slide highlights a strategic partnership/supply agreement as a form of business traction.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
15
The slide highlights that THIO has a better safety profile than standard chemotherapy, which typically has 70-80% incidence of Grade 3-5 side effects.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
17
Data presented in a table format with specific clinical definitions for DCR and treatment lines.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
28
The slide presents two line charts showing tumor volume reduction over time for different treatment regimens in SCLC and HCC mouse models.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
29
The chart shows a clear divergence between the control group (increasing tumor volume) and the THIO group (decreasing tumor volume to near zero).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
30
The slide shows two line charts representing tumor volume over time in HCC models, highlighting the efficacy of THIO and THIO+Libtayo combinations.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
39
The slide serves as a milestone marker for the company's public listing.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
09
The slide uses a 3-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
14
The slide features a thumbnail of a scientific poster presentation.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
09
The slide uses a 3-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Traction1 hit
15
The slide features a thumbnail of a scientific poster presentation.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit